TimesSquare Capital Management LLC Buys 110,630 Shares of Cellebrite DI Ltd. $CLBT

TimesSquare Capital Management LLC boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 715,992 shares of the company’s stock after purchasing an additional 110,630 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Cellebrite DI were worth $12,909,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CLBT. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Cellebrite DI by 40.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after buying an additional 103,568 shares in the last quarter. Norwood Investment Partners LP bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $4,274,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $19,457,000. Wisconsin Capital Management LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $1,649,000. Finally, Granite Investment Partners LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at $11,406,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

CLBT opened at $13.46 on Wednesday. The stock has a 50-day moving average price of $13.47 and a 200-day moving average price of $15.45. The firm has a market cap of $3.36 billion, a PE ratio of 48.07, a P/E/G ratio of 1.63 and a beta of 1.15. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CLBT. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is owned by insiders.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.